Navigation Links
Clemson researchers develop sticky nanoparticles to fight heart disease
Date:2/18/2014

CLEMSON, S.C. Clemson University researchers have developed nanoparticles that can deliver drugs targeting damaged arteries, a non-invasive method to fight heart disease.

Heart disease is the leading cause of death in the U.S., according to the Centers for Disease Control and Prevention. One of the standard ways to treat clogged and damaged arteries currently is to implant vascular stents, which hold the vessels open and release such drugs as paclitaxel.

The researchers, led by Clemson bioengineering professor Naren Vyavahare, hope their advanced nanoparticles could be used alongside stents or in lieu of them.

"Healthy arteries have elastic fibers that provide elasticity. They are like rubber bands in the tissue that allow expansion and recoil during blood flow," Vyavahare said. "In most cardiovascular diseases, elastic fibers in arteries get damaged, creating hooks that can be used to target drugs."

The nanoparticles, coated with a sticky protein, latch onto damaged arteries and can deliver a drug to the site in slow release fashion. These nanoparticles can be engineered to deliver an array of drugs to the damaged or clogged artery, a common example being paclitaxel, which inhibits cell division and helps prevent growth of scar tissue that can clog arteries. These particles also have unique surfaces that allow prolonged circulation time, providing more opportunities for these particles to accumulate at the damage site.

"We developed nanoparticles that have antibodies on the surface that attach to diseased sites like Velcro," said Vyavahare. "Interestingly, these newly created nanoparticles only accumulate at the damaged artery, not in the healthy arteries, enabling site-specific drug delivery."

"These nanoparticles can be delivered intravenously to target injured areas and can administer drugs over longer periods of time, thus avoiding repeated surgical interventions at the disease site," said Aditi Sinha, a Clemson graduate student and lead author on a paper soon to be published in journal Nanomedicine: Nanotechnolgy, Biology and Medicine.

The work is a promising step toward new treatments for cardiovascular and other diseases. The research team is testing the nanoparticles to determine the most effective drug dosage for vascular tissue repair. This technology can have variety of applications in other diseases, such as chronic obstructive pulmonary disease, Marfan syndrome and elastic fiber-related disorders, such as aortic aneurysms.


'/>"/>
Contact: Naren Vyavahare
narenv@clemson.edu
864-656-5558
Clemson University
Source:Eurekalert

Related medicine news :

1. Clemson professor awarded nearly $600,000 4-year grant to study language of plants
2. Clemson researcher awarded nearly $245,000 to study automation trust and dependence
3. Clemson researchers collect and reuse enzymes while maintaining bioactivity
4. Clemson bioengineering team wins undergraduate design competition
5. Clemson, GHS create healthcare research powerhouse
6. Clemson, Dartmouth use $1.5M grant to develop mobile health technology
7. Clemson researcher to present at Connecticuts youth concussion conference
8. NIH awards $20 million over 5 years to train next generation of global health researchers
9. Researchers develop a new cell and animal model of inflammatory breast cancer
10. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
11. Researchers Find Gene Mutations That May Be a Key to Autism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Augustine ... services to families and business owners in the greater Dallas metropolitan area, is ... Dallas Fallen Officer Foundation. , Established in 2009 by active police professionals in ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Sharon Kleyne, ... Global Climate Change and Your Health on Voice of America, declared on her radio ... call attention to the fact that when these bullies attack leaders in corporate America, ...
(Date:12/7/2016)... ... 07, 2016 , ... 1105 Media’s Live From program has ... Awards competition. Live From won in the Use of Social Media category. The ... projects undertaken by the media industry’s most innovative marketing professionals. , ...
(Date:12/7/2016)... ... 2016 , ... Maureen McLaughlin, LA.c., a certified acupuncturist, is ... Connecticut (RMACT). McLaughlin brings nearly 20 years of experience with fertility patients to ... their family building goals. Acupuncture helps fertility patients by supporting the ...
(Date:12/7/2016)... Va. (Dec. 3, 2016) , ... (PRWEB) December ... ... nation’s only patient advocacy nonprofit for individuals impacted by cerebral cavernous angiomas, was ... in New Mexico with a patient engagement program. New Mexico has more people ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)...   Arena Pharmaceuticals, Inc. (NASDAQ: ... in the ralinepag phase 2 trial.  Ralinepag is an ... for the treatment of pulmonary arterial hypertension (PAH). The ... "This marks an important step in the development ... on our pipeline," said Amit Munshi , Arena,s ...
(Date:12/7/2016)... Conn. , Dec. 7, 2016 According to ... in more than one-third (38%) of patients with non-small cell ... epidermal growth factor receptor (EGFR) genetic mutation status. The findings ... ( LBA ID #6067 #P3.02b ) at the ... Vienna, Austria . The survey results revealed ...
(Date:12/7/2016)... LONDON , Dec. 7,2016  Based ... drug delivery industry, Frost & Sullivan recognizes ... Frost & Sullivan Award for Enabling Technology ... plug the loopholes in traditional drug delivery ... and liquid microneedle-based drug delivery technologies, Memspatch ...
Breaking Medicine Technology: